glp-1 and breast cancer risk Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence 🎗️ Women taking GLP-1 medicines

Byetta and other early GLP-1 agonists immediately acted and required a once or twice-a-day dosage

Pasireotide could drastically suppress GLP-1 secretion induced by Gs-cAMP signals through SSTR5-Gi-dependent inhibition of cAMP levels, effectively blocking the main pathways

Trends in GLP-1 use From 2015 to 2024, GLP-1 uptake after an index event in patients with diabetes increased modestly but remained low

Despite extensive research, significant gaps remain in the causal pathways linking depression and diabetes

Type 1 diabetes is caused by a lack of insulin due to destruction of the beta cells, which prevents glucose uptake from the blood